June 6, 2018 News by Patricia Inacio, PhD #CMSC2018 – Gains in Functional Abilities Seen in Lemtrada-treated MS Patients Over Six Years, CARE-MS II Extension Study Shows Patients with active relapsing-remitting multiple sclerosis (MS) continue to show improvement ā lesser functional disability across a variety of measures ā and often without the need for continuous treatment after takingĀ LemtradaĀ for two years, according to six-year results from the CARE-MS II extension study. These results were shared in a…
May 26, 2017 News by Patricia Silva, PhD #CMSC17 – Relapse After First Lemtrada Course No Indication of Poor Long-Term Outcome, Study Finds Multiple sclerosis (MS) patients who experienced a relapse between their first and second rounds of Lemtrada (alemtuzumab) had good treatment outcomes over the long run, according to a Phase 3 clinical trial. Those who relapsed after their first round ended up with annual relapse rates similar to those who didn’t…
April 26, 2017 News by Joana Fernandes, PhD Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The new data will be presented at the American Academy of Neurology (AAN) Annual MeetingĀ taking…
December 2, 2016 News by Patricia Inacio, PhD Lemtrada Lessens MS Disability in People Who Respond Poorly to Other Therapies, Study Says Data from the CARE-MS II clinical trialĀ showed that Lemtrada (alemtuzumab) canĀ lessen pre-existing disabilities in patients with relapsing-remitting multiple sclerosis (RRMS) who failed to respond adequately to previous disease-modifying therapies, according to a study of the trial’s data. The treatment was evaluated againstĀ Rebif (interferon beta-1a)Ā therapy. The study, āAlemtuzumab…
October 17, 2016 News by Patricia Silva, PhD Lemtrada Seen to Help Reverse MS Disability in People in Earlier Stages of Disease Lemtrada (alemtuzumab) was seen to help reverse disability among patients with relapsing forms of multiple sclerosis (MS) in relatively early stages of the disease, researchers report. The study, āAlemtuzumab improves preexisting disability in active relapsing-remitting MS patients,ā published in the journal Neurology, supports the idea that treatment…
August 29, 2016 News by Patricia Silva, PhD Lemtrada to Treat Relapsing MS Now Part of New Brunswick, Canada, Drug Program The Government ofĀ New Brunswick added Ā Lemtrada (alemtuzumab), byĀ Sanofi Genzyme,Ā to the New Brunswick Prescription Drug Program (NBPDP) through special authorization for eligibleĀ patients with relapsing-remitting multiple sclerosis (RRMS). New BrunswickĀ joins other Canadian provinces, includingĀ Ontario, Saskatchewan,Ā Quebec, and Manitoba, in making this treatment available to RRMS patients, ages 18 andĀ older,Ā who have had…
October 12, 2015 News by Patricia Silva, PhD Update on Alemtuzumab (Genzyme’s Lemtrada) Clinical Trial Data Presented at ECTRIMS 2015 Multiple Sclerosis News Today recently attended the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā held in Barcelona, Spain, October 7 to 10, 2015. On Friday, October 9, three parallel sessions entitled āFree Communicationsā took place. In the first session, several topics related to multiple…
May 1, 2015 News by admin Genzyme’s LEMTRADA Maintain’s Effectiveness in Reducing Brain Atrophy According to Recent Study Results GenzymeĀ presentedĀ new magnetic resonance imaging (MRI) data from the LemtradaĀ® (alemtuzumab) clinical development programĀ onĀ April 23, 2015, at the 67th American Academy of Neurology (AAN) Annual Meeting. The company showed that in the extension phase of two Phase III trials (years 3 and 4), the drug continued to protect the nervous…